Evidence map›Paper›PMID 41062956›Full record

ArticleBMC cancer2025

Lifetime stressor exposure and depression among patients with pancreatic cancer: insights from the Florida Pancreas Collaborative.

Anthony DeSomma, Sebastian Maletz, Toni L Basinski, Raiza Morales, Tiago Biachi de Castria, Mark Bloomston, Dung-Tsa Chen, Wade G Douglas, Kevin L Huguet, Daniel Jeong and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anthony DeSommaDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Sebastian MaletzUniversity of South Florida Health Morsani College of Medicine, Tampa, FL, USA.
Toni L BasinskiDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Raiza MoralesDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Tiago Biachi de CastriaDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Mark BloomstonRegional Cancer Center, Fort Myers, FL, USA.
Dung-Tsa ChenDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
Wade G DouglasDepartment of Clinical Scienes, Division of Surgery, Florida State University College of Medicine, Tallahassee Memorial Healthcare, Tallahassee, FL, USA.
Kevin L HuguetDepartment of Surgery, St. Anthony's Hospital, St. Petersburg, FL, USA.
Daniel JeongDepartment of Diagnostic Imaging, Moffitt Cancer Center, Tampa, FL, USA.
Kun JiangDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Dae Won KimDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Anjuli LuthraDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Jose M PimientoDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Sahana RajasekharaDepartment of Supportive Care Medicine, Moffitt Cancer Center, Tampa, FL, USA.
Vic VelanovichUniversity of South Florida, Tampa General Hospital, Tampa, FL, USA.
Margaret A ParkDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA.
Grant S ShieldsDepartment of Psychological Science, University of Arkansas, Fayetteville, AR, USA.
George M SlavichDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Jennifer B PermuthDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. jenny.permuth@moffitt.org.

Funding

California Governor's Office of Planning and Research/California Initiative to Advance Precision Medicine (supported GMS) #OPR21101Department of Defense Health Program Congressionally Directed Medical Research Program (awarded to JPB) W81XWH-22-1-1021 LOG#PA210192James and Esther King Biomedical Research Program, Florida Department of Health (awarded to J.B.P) #8JK02
6 · The paper itself

Abstract

backgroundAlthough depression is reported to be higher among patients with pancreatic cancer than in the general population, research on depression and stress levels in this population is limited.

methodsTo address this gap, we investigated the prevalence of self-reported depression and lifetime stressor exposure in a cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma (PDAC) or other types of pancreatic tumors such as pancreatic neuroendocrine tumors and intraductal papillary mucinous neoplasms who received care at one of 15 institutions participating in the multi-institutional study Florida Pancreas Collaborative. Depression severity was assessed using the Edmonton Symptom Assessment System-revised (ESAS-r) and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC), and acute and chronic stressor exposure was assessed with the Stress and Adversity Inventory (STRAIN).

resultsPDAC patients reported higher average depression symptom severity at the time of diagnosis and after 6 months compared to non-PDAC patients (p = 0.027 and p = 0.063, respectively). On the other hand, non-PDAC patients experienced a higher mean number and severity of lifetime stressors (p = 0.021 and p = 0.039, respectively) than PDAC patients. Across the sample, greater stressor exposure (measured by stressor count, severity, and event type) was associated with higher odds of clinically significant depressive symptoms. We also observed that chronic stressors were significantly associated with lower odds of advanced disease (OR = 0.896, p = 0.002). Among PDAC patients who completed both STRAIN and ESAS-r (n = 52), greater severity of acute life events was associated with a significant increase in ESAS-r depression scores between baseline and 6-month follow-up (p = 0.015).

conclusionsThese findings highlight distinct patterns of depression and stress across pancreatic tumor types and reveal a robust association between lifetime stress exposure and depressive symptoms. Together, they underscore the need for systematic screening and integrated psychosocial support for patients with pancreatic cancer.

Indexed as

Carcinoma, Pancreatic DuctalDepressionPancreatic NeoplasmsStress, PsychologicalAgedAged, 80 and overFemaleFloridaHumansMaleMiddle AgedPrevalenceQuality of LifeAdversityDepressionLifetime stressPancreatic cancer

Identifiers

PMID41062956
PMCPMC12506433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.